GLP-1 Safety Alerts & FDA Updates
We monitor FDA announcements daily for warning letters, safety updates, and enforcement actions related to GLP-1 medications and weight loss providers.
FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
The FDA approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss in certain adult patients. This approval marks the fourth product approved under the Commissioner's National Priority Voucher pilot program.
View FDA SourceFDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
The FDA issued 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites. This enforcement action targets illegal marketing practices by telehealth providers offering weight loss services.
View FDA SourceWhat to Do If Your Provider Is Flagged
An FDA alert does not always mean your medication is unsafe. Many alerts are administrative or related to labeling and marketing practices, not product safety.
Read the full FDA notice linked in the alert. Understand whether the issue affects the medication you are taking or only certain product batches or business practices.
Ask your provider about the alert and what steps they are taking in response. A reputable provider will be transparent about any FDA communications.
Your primary care physician can help you evaluate whether to continue, pause, or switch your GLP-1 treatment based on the specific alert and your health history.
If you experience adverse effects or suspect a safety issue, report it directly to the FDA through their MedWatch program at fda.gov/medwatch.
Find a Verified Provider
Search our directory of 9,500+ verified GLP-1 clinics to find a provider you can trust.